OREANDA-NEWS. April 09, 2009. The Federal Antimonopoly Service (FAS Russia) analyzed the market of medicines for treatment of hemophilia, cystic fibrosis, hypophysial nanism, Gaucher disease, myeloleukemia, multiple sclerosis as well as medicines applied after transplantation of organs and (or) tissues, reported the press-centre of FAS Russia.

As part of the analysis, FAS Russia examined substitutability of medicines and calculated market shares of the distributors that supply medicines and distribute them in the wholesale markets of the Russian Federation. Market shares were calculated on the amount of sales объема продаж in physical terms based on information received from the owners of registration certificates and distributors of relevant trade names of medicines.

On 3rd April 2009 FAS Russia issued No.193 order in including the flowing economic entities in the Register of economic entities that control over 35% of the relevant goods market or have dominant position on the relevant goods market, if the federal laws specify the cases for recognizing dominant position of economic entities:

"IHCC" Ltd.,

"Johnson& Johnson" Ltd.,

"Galen Pharma" Ltd.,

"Roche-Moscow" CJSC,

"Novartis Pharma" Ltd.,

"BIOTECH" Ltd.,

"Nycomed Distribution Center" Ltd.,

"Schering AG" CJSC,

"Astellas Pharma" CJSC,

"Novo Nordisk" Ltd.

The Order is aimed at preventing and discovering antimonopoly violations among suppliers of medicines for treatments of the above-listed diseases.

Currently FAS Russia is working on compiling the Register of economic entities, which control over 35% of the market of medicines, in all regions of the Russian Federation.